key: cord-0801093-2jei05lk
authors: Chiotos, Kathleen; Hayes, Molly; Kimberlin, David W; Jones, Sarah B; James, Scott H; Pinninti, Swetha G; Yarbrough, April; Abzug, Mark J; MacBrayne, Christine E; Soma, Vijaya L; Dulek, Daniel E; Vora, Surabhi B; Waghmare, Alpana; Wolf, Joshua; Olivero, Rosemary; Grapentine, Steven; Wattier, Rachel L; Bio, Laura; Cross, Shane J; Dillman, Nicholas O; Downes, Kevin J; Timberlake, Kathryn; Young, Jennifer; Orscheln, Rachel C; Tamma, Pranita D; Schwenk, Hayden T; Zachariah, Philip; Aldrich, Margaret; Goldman, David L; Groves, Helen E; Lamb, Gabriella S; Tribble, Alison C; Hersh, Adam L; Thorell, Emily A; Denison, Mark R; Ratner, Adam J; Newland, Jason G; Nakamura, Mari M
title: Multicenter initial guidance on use of antivirals for children with COVID-19/SARS-CoV-2
date: 2020-04-22
journal: J Pediatric Infect Dis Soc
DOI: 10.1093/jpids/piaa045
sha: f71093501ded729b5b30edf43438059671591d00
doc_id: 801093
cord_uid: 2jei05lk

BACKGROUND: Although Coronavirus Disease 2019 (COVID-19) is mild in nearly all children, a small proportion of pediatric patients develops severe or critical illness. Guidance is therefore needed regarding use of agents with potential activity against severe acute respiratory syndrome coronavirus 2 in pediatrics. METHODS: A panel of pediatric infectious diseases physicians and pharmacists from 18 geographically diverse North American institutions was convened. Through a series of teleconferences and web-based surveys, a set of guidance statements was developed and refined based on review of best available evidence and expert opinion. RESULTS: Given the typically mild course of pediatric COVID-19, supportive care alone is suggested for the overwhelming majority of cases. The panel suggests a decision-making framework for antiviral therapy that weighs risks and benefits based on disease severity as indicated by respiratory support needs, with consideration on a case-by-case basis of potential pediatric risk factors for disease progression. If an antiviral is used, the panel suggests remdesivir as the preferred agent. Hydroxychloroquine could be considered for patients who are not candidates for remdesivir or when remdesivir is not available. Antivirals should preferably be used as part of a clinical trial if available. CONCLUSIONS: Antiviral therapy for COVID-19 is not necessary for the great majority of pediatric patients. For those rare children who develop severe or critical disease, this guidance offer an approach for decision-making regarding antivirals, informed by available data. As evidence continues to evolve rapidly, the need for updates to the guidance is anticipated.

In December 2019, a novel coronavirus, since named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in Wuhan, Hubei Province, China, as the cause of a severe respiratory disease, Coronavirus Disease 2019 . COVID-19 has been declared a pandemic by the World Health Organization (WHO), with cases detected in over 180 countries and affecting nearly 2 million people as of April 14, 2020, including over 600,000 in the United States (US) (1) . Over 126,000 people have died from the infection worldwide.

In light of this public health crisis, there has been significant interest in identifying therapies that include both novel and "repurposed" drugs with antiviral activity against SARS-CoV-2 that may mitigate disease severity. As of the writing of this guidance on April 14, 2020 , no agent has been identified with proven efficacy against SARS-CoV-2. Further, while the evidence base evolves almost daily, the data supporting candidate medications for COVID-19 are sparse, based primarily on in vitro studies, animal models, and small clinical studies focused on adults, with only sporadic case series describing antiviral use in children (2) (3) (4) (5) .

While pediatricians are accustomed to prescribing medications that have been studied primarily in adults, using this approach for COVID-19 presents unique challenges for several reasons. First, the evidence base evaluating all potentially active antivirals for treatment of COVID-19 is extremely limited. Second, COVID-19 appears to be far milder in the great majority of children compared with adults (6) , raising questions as to whether the potential benefits of antivirals are also much lessand if so, whether the threshold for using these medications should be much higher, especially given possible harms. Third, the optimal pathway for introducing novel therapies, even in a pandemic, is to do so as part of well-designed, randomized controlled trials (3) . As of April 14, 2020 , no clinical trials A c c e p t e d M a n u s c r i p t 8 in the US are enrolling children <12 years old, so antiviral use in children is largely limited to off-label prescribing of agents approved by the Food and Drug Administration (FDA) for other indications or Single Patient Expanded Access requests for investigational agents such as remdesivir.

Absent clinical trials, and through the SHaring Antimicrobial Reports for Pediatric Stewardship (SHARPS) Collaborative (7), the potential value of multicenter, expert guidance for use of antivirals in children with COVID-19 during this pandemic became increasingly apparent. Herein, we outline our approach to developing this guidance, summarize the relevant available evidence, and outline the rationale for our suggested treatment approach. We remind the reader that this document is not a guideline, and we emphasize the ongoing importance of critical review of emerging literature to inform current and future treatment decisions. We also refer the reader to guidelines published by the Infectious Diseases Society of America (8) .

A panel of pediatric infectious diseases (ID) physicians and pharmacists from 18 geographically diverse North American institutions was convened. Through a series of teleconferences and webbased surveys, a set of guidance statements was developed and refined based on best available evidence and expert opinion. Given the overall limited nature of the data, a systematic review was not performed, nor was the available evidence formally evaluated using Grading of Recommendations Assessment, Development, and Evaluation (GRADE) or other methodology. This guidance document has been reviewed and endorsed by the Pediatric Infectious Diseases Society.

A c c e p t e d M a n u s c r i p t 9

Because the quality of evidence considered by the expert panel was generally low, the final guidance statements integrate both the panel's assessment of the evidence quality and the ratio of risk and benefit from the treatment or action. We assert that the key guiding principle should be to "first do no harm," especially given the unknown efficacy of proposed antivirals and their established-or, in the case of novel agents, not yet fully characterized-potential harms. This principle is especially important because as discussed in detail below, available evidence indicates that pediatric outcomes for COVID-19 are favorable overall. A statement of "suggest" reflects the panel's view that there is a weighting towards risk or benefit from the proposed therapy or action. A statement of "consider" reflects the panel's uncertainty as to whether there is risk or benefit from the proposed therapy or action. Within "consider" statements, the panel further delineates interventions that "could" be considered, meaning that different choices regarding the action or therapy are likely to be appropriate for different patients, or "should" be considered, meaning that the potential risks of the action or therapy would generally be accepted by most individuals, given the potential for (yet unproven) benefit.

The panel considered four major questions related to antiviral therapy for children with COVID-19: A c c e p t e d M a n u s c r i p t 10 For each of these broad questions, we have provided one or more relevant guidance statements using the definitions above.

Guidance statement: The suggested approach for nearly all children with COVID-19 is supportive care. Antivirals may be considered on a case-by-case basis. When antiviral therapy is considered, we recommend enrollment in clinical trials as these become available for pediatric patients to study the efficacy and safety of potential antivirals. Otherwise, antivirals should be offered with appropriate monitoring and in consultation with a pediatric ID specialist whenever possible.

Rationale: As discussed below, multiple large epidemiologic studies have demonstrated that the overwhelming majority of children with COVID-19 experience a mild, self-limited illness, with only rare reports of more severe disease manifestations in children, including respiratory failure or shock.

Given the lack of evidence of efficacy for any antiviral and the possible harms of these medications, the risk-benefit ratio for most pediatric patients therefore tips toward supportive care as the primary management strategy, especially outside the setting of a clinical trial. Absent availability of clinical trials, and per the WHO, provision of experimental therapies to individual patients on an emergency basis can be appropriate if "no proven effective treatment exists; it is not possible to initiate clinical studies immediately; the patient or his or her legal representative has given informed consent; and the emergency use of the intervention is monitored, and the results are documented and shared in a timely A c c e p t e d M a n u s c r i p t 11 manner with the wider medical community (2) ."

Guidance statement: The panel suggests antiviral agents be considered only in children with positive virologic COVID-19 testing.

Rationale: The clinical presentation of COVID-19 in children overlaps significantly with other infections. No clinical, radiographic, or laboratory criteria are sufficiently specific to distinguish COVID-19 from these other pediatric conditions. Administration of potentially active antivirals without confirmation of SARS-CoV-2 infection poses a significant risk of exposing patients to unnecessary harms from these medications without the possibility of benefit. Further, such an approach depletes finite-and in some cases scarce-supplies of possibly efficacious agents for COVID-19, as well as supplies for patients reliant on them for other conditions. A rare exception might be made for critically ill patients with a high suspicion for COVID-19 (based on a highly consistent clinical presentation combined with high local prevalence or known contact with a confirmed case) for whom a significant delay in COVID-19 test results is anticipated. In such a scenario, empiric initiation of antiviral therapy could be considered.

A c c e p t e d M a n u s c r i p t 12 Clinical evidence of lower respiratory tract disease based on respiratory support requirement Guidance statement: The panel suggests that clinical criteria, and specifically respiratory support requirements, be used to define scenarios in which use of antiviral agents is considered.

Rationale: Because no available evidence supports a benefit of antiviral treatment for pediatric patients with COVID-19 with specific clinical features or disease severity, the panel concluded that the risks of unproven therapy were most tolerable in those patients with more severe illness, such as those with evidence of lower respiratory tract disease requiring escalation of respiratory support.

Both clinical and radiographic criteria were considered to define this population, but because radiographic infiltrates are common, even among well-appearing children with respiratory viral infections, respiratory support requirement was favored as the more objective and therefore relevant measure (9).

Guidance statement: Outpatients and hospitalized patients with mild or moderate COVID-19 should be managed with supportive care only, without antiviral agents.

Rationale: We regard COVID-19 cases as "mild" or "moderate" if there is no new supplemental oxygen requirement (or no increased requirement for patients who require supplemental oxygen at baseline) ( Table 1 ). Available data suggest that the overwhelming majority of children with mild or moderate disease recover with supportive care alone. Administration of antivirals early in the disease course to prevent progression thus does not seem warranted, especially given that use of these agents would expose large numbers of patients unnecessarily to the possible harms of these A c c e p t e d M a n u s c r i p t 13 drugs. A rare exception might be outpatients who require an increase from baseline chronic respiratory support that can be managed at home with family expertise and/or home nursing.

COVID-19 in most children is of mild or moderate severity (6, (10) (11) (12) . A Chinese report including 72,314 patients revealed that patients aged ≤19 years accounted for only 2.1% of all cases, despite this age group's comprising approximately 23% of the country's population (12, 13) . A case series published by Dong and colleagues demonstrated that among 2,143 confirmed and suspected pediatric cases in China, >90% had asymptomatic, mild, or moderate infections, where moderate disease was defined as pneumonia with fever, cough, and possible abnormalities on chest imaging but no hypoxemia or shortness of breath (11). The experience thus far in the US parallels that from Chinese reports. Among 508 patients hospitalized with COVID-19 between February 12 and March 6, only 2%-3% were ≤19 years of age, and none in this age group required admission to an intensive care unit (ICU) or died (6) . A subsequent report on COVID-19 in US children indicated that among 745 with available hospitalization status, only 147 (estimated range 5.7%-20%) were hospitalized (14) . A c c e p t e d M a n u s c r i p t 14 Rationale: We regard COVID-19 cases as "severe" if there is a new significant requirement for supplemental oxygen (or an increased requirement from baseline) without the need for new or increased non-invasive or invasive mechanical ventilation (Table 1) . Most children with this disease severity will recover with supportive care alone. Use of potentially active antivirals could be considered on a case-by-case basis, taking into account underlying medical conditions and health status that may confer risk for progression to more serious illness, as well as the overall clinical trajectory. Of note, there is no robust evidence at this time that any underlying pediatric medical condition is associated with a more severe disease course. We discuss below considerations for hypothesized at-risk populations of concern to help inform case-by-case assessments.

Guidance statement: Supportive care alone may be appropriate for some children with critical COVID-19. Use of potentially active antivirals should be considered, preferably as part of a clinical trial if available.

Rationale: We regard COVID-19 cases as "critical" if there is a new or increased need for noninvasive or invasive mechanical ventilation, or there is sepsis or multi-organ failure, OR there is a rapidly worsening clinical trajectory that does not yet meet these criteria ( Table 1 ). The contribution to critical COVID-19 of direct viral infection versus a deleterious immune response is not yet well understood (15) . However, in contrast with mildly or moderately ill patients, those with critical disease have to some extent already failed supportive therapy, such that to the degree that antiviral effects might be helpful, the risks of these therapies may be more acceptable and outweighed by the potential benefits. Although rare, critical disease and fatalities have been reported in a small number of children with COVID-19 (14, 16) . In the pediatric case series by Dong and colleagues, 13 (0.6%) of the 2,143 cases had respiratory failure, acute respiratory distress syndrome (ARDS), encephalopathy, myocardial injury or cardiac failure, acute kidney injury, shock, or coagulation dysfunction (11). The US pediatric case series demonstrated that of 745 COVID-19 infected patients, 15 (estimated range 0.58%-2.0%) were admitted to an ICU, and 3 died (14) .

Guidance statement: There are no definitive data to support any specific risk factor for severe COVID-19 in children.

Rationale: There are no robust data demonstrating specific risk factors for severe disease in children, nor are there data that antivirals mitigate disease severity in any population. To therefore avoid treatment misallocation in the absence of well-defined pediatric risk factors, we have instead summarized proposed risk factors (Table 2 ). These include risk factors for severe illness extrapolated from adult data (including cardiovascular disease, pulmonary disease, diabetes, cancer, and obesity) or identified for other respiratory viral infections (including young age, immunocompromise, cardiovascular disease, and pulmonary disease). Rather than impose a classification scheme for initiation of antivirals based on these proposed risk factors, we have summarized considerations relevant to each hypothesized risk factor to inform case-by-case discussions.

A c c e p t e d M a n u s c r i p t 16

The early report on COVID-19 in US children offered limited analyses of age and underlying conditions. Among 95 children aged <1 year with known hospitalization status, 59 (estimated range 15%-62%) were hospitalized, and five required ICU admission. In contrast, among those aged 1-17 years, the percentage hospitalized was lower (estimated range 4.1%-14%) and varied little among age groups. Among the 345 children with available information on underlying conditions, 80 (23%) had ≥1 underlying condition, with the most common including chronic lung disease, cardiovascular disease, and immunosuppression. However, the authors note significant potential sources of bias, including missing data on severity and underlying conditions for a majority of cases, with data unlikely to be missing at random; incomplete follow-up for many patients; and geographic variation in test practices, with many areas prioritizing testing for more severely ill patients, probably leading to overestimates of the percentage of patients hospitalized in all age groups (14) .

The pediatric cohort described by Dong and colleagues is the largest to date and included 379 children in the <1-year category. Of these, a majority (339, 89.4%) had mild to moderate symptoms or were asymptomatic. Multiple other reports also have described children 1 to 11 months of age with only mildly symptomatic infection who improved without intervention (17, 18) . Similarly, early data from Italy report no mortality in the 0-to 19-year age group (19) . In the preliminary description of COVID-19 in US children described above, among 147 hospitalized children, 5 out of 59 (8%)

infants <1 year of age required ICU-level care, compared with 10 of 88 (11%) children >1 year of age, suggesting that young age is not associated with increased risk of severe disease (14) . Currently available data are insufficient to establish whether immunocompromised children are at greater risk of severe COVID-19 than healthy children or those with other comorbidities (6, 20) .

Limited data suggest that children with mild or moderate immunocompromise are not at high risk of severe infection (21) . Reports from China demonstrate that adults with COVID-19 and malignancies have increased mortality compared with patients of similar ages (22, 23) . In a nationwide Chinese cohort, malignancy was an independent risk factor for mortality after adjusting for age and smoking status (24) . However, many other confounding risk factors were present, including other comorbid conditions (25) . Considering the limited available data in SARS-CoV-2-infected patients, and extrapolating from other viruses, children with severe T-cell deficiency or dysfunction may be at risk of more severe disease and may exhibit longer viral shedding than non-immunocompromised children (Table 3) . To the extent possible, we suggest reducing T-cell immunosuppression in infected children. Finally, the A c c e p t e d M a n u s c r i p t 18 potential for drug toxicity and drug-drug-interactions given the numerous medications that immunocompromised patients receive warrants special consideration prior to initiation of antiviral therapy.

Adult data suggest that, in addition to older age, presence of cardiovascular disease, chronic respiratory disease, hypertension, or cerebrovascular disease is associated with COVID-19-related morbidity and mortality (25, (33) (34) (35) . In contrast, no available data have demonstrated an association between any underlying medical condition and morbidity and mortality in children with COVID-19.

However, there is evidence to support more severe outcomes from other respiratory viral infections, such as influenza (36, 37) , parainfluenza (38) , RSV (39) (40) (41) (42) , and non-COVID-19 coronaviruses (26,43), in children with chronic cardiac and pulmonary conditions. These conditions could therefore be considerations when weighing risks and benefits of potential antiviral therapy (Table 3) .

There are limited data on overweight (BMI >85 th -95th percentile for age and sex) or obesity (BMI ≥ 95 th percentile for age and sex) as independent risk factors for severe manifestations of COVID-19 in adults; some of these data derive from retrospective studies that are awaiting peer review (44) (45) (46) .

Overweight and obesity may be independent risk factors of more severe COVID-19, as well as severe pneumonia during hospitalization due to COVID-19. While the authors report controlling for potential confounders, patients had several related comorbidities, including diabetes; hypertension; cardiovascular, renal or liver disease; and cancer. Overweight and obesity are common conditions in the pediatric population, but comorbid cardiovascular disease in particular does not commonly complicate these conditions in children. Overweight and obesity may, however, put pediatric A c c e p t e d M a n u s c r i p t 19 patients at higher risk for poor respiratory outcomes due to impaired lung mechanics (47) . When contemplating use of a potentially active antiviral in a pediatric patient with COVID-19, we suggest that overweight and obesity, with their associated comorbidities, could be considered in the decision-making process but should not be the sole rationale for choosing to administer antiviral therapy.

Based on observational data in adults, individuals with diabetes mellitus appear to be at elevated risk for several complications of COVID-19, including progression to severe disease, development of ARDS, and in-hospital death (23, 25, 48) . However, adult patients in these early case series often have had comorbid conditions in addition to diabetes mellitus, including cardiovascular and/or renal disease; multiple comorbidities were common among the patients with severe disease. Caution is warranted in extrapolating these data to pediatric patients with diabetes mellitus. Important differences between children and adults may include the prevalence of associated cardiovascular disease and use of concomitant medications acting on the renin-angiotensin-aldosterone system (which are hypothesized to affect individual risk for development of severe COVID-19-associated complications) (49) . Additionally, possible differences in risk for severe COVID-19 disease between individuals with type 1 versus type 2 diabetes are not understood at this time. When considering use of a potentially active antiviral in a pediatric patient with COVID-19, we suggest that diabetes mellitus and associated comorbidities could be considered in the decision-making process but should not be the sole rationale for choosing to administer antiviral therapy.

A c c e p t e d M a n u s c r i p t 20

There are no antivirals with proven efficacy for the treatment of COVID-19 as of April 14, 2020. All antiviral use should therefore be considered experimental. Antivirals should be tested in clinical trials, as this is the only way to establish efficacy and safety of these therapies for COVID-19. Use of antivirals outside of a clinical trial, either through Single Patient Expanded Access ("compassionate use") requests, expanded access programs, or off-label use of FDA-approved medications, provides no way to evaluate the efficacy of these therapies, exposes patients to potential harms with no mechanism to quantify these harms, and does not offer human subjects protections that would be provided in clinical trials. However, as of April 14, 2020, no randomized trials studying potentially active antivirals were enrolling children <12 years old in the US. The panel therefore acknowledges that there may be clinical scenarios in which providers may accept the potential harms of experimental therapy for a chance of (yet unproven) benefit in a child. If used, we remind the reader of the importance of compliance with local institutional and regulatory policies for experimental therapies, with appropriate monitoring for toxicity and the input of a pediatric ID consultant. To aid clinicians in decision-making surrounding antiviral therapy, we provide a narrative summary of available evidence for several proposed antiviral agents. We have prioritized discussion of studies conducted on SARS-CoV-2 and those conducted in humans to the extent possible.

Guidance statement: If an antiviral is used, the panel suggests use of remdesivir as the preferred agent, preferably as part of a clinical trial if available.

Rationale: In vitro and animal data support the biologic plausibility of remdesivir's activity against SARS-CoV-2, and available published data suggest that it is generally well tolerated (50, 51) . Use of A c c e p t e d M a n u s c r i p t 21 remdesivir under Single Patient Expanded Access ("compassionate use") requests, the major mechanism currently available to patients <18 years of age, offers the additional advantages (relative to off-label use of other antivirals) of a mechanism for monitoring at least serious adverse events (SAEs) through data collection by the manufacturer, oversight by local Institutional Review Boards, and a requirement for informed consent.

Remdesivir is a nucleoside analog prodrug which, when activated, binds to viral RNA-dependent RNA polymerase, resulting in premature RNA chain termination. While other nucleoside analogs (e.g., ribavirin) are ineffective against coronaviruses due to the proofreading capability of a unique 3'-to-5' exoribonuclease and resultant high-fidelity viral replication, remdesivir appears to maintain activity despite this exoribonuclease (52, 53) . Moreover, in vitro studies demonstrate a high threshold for developing resistance, and when present, resistance results in a loss of viral fitness, further supporting the potential role of this agent (53) . Remdesivir is not FDA approved for any indication but has been studied for the treatment of Ebola virus disease (EVD) (50) . 

Pharmacokinetic studies of remdesivir have been performed, but primary data have not been published (59) . Remdesivir has been studied in a randomized trial comparing it to three monoclonal antibodies (mAb114, Zmapp, and REGN-EB3) for the treatment of EVD. The remdesivir arm of this study was terminated early after a total of 681 patients were enrolled in the trial, as both MAb114 and REGN-EB3 were superior. Among 175 patients treated with remdesivir, 43 were under age 18, including two patients less than a week old. There was a single SAE potentially attributed to remdesivir, which was infusion-related hypotension in a 41-year-old man (50) .

Published data describing use of remdesivir for COVID-19 include a case report and case series (60) (61) (62) . In a non-peer-reviewed case series describing the early US experience with COVID-19, three adults were treated with remdesvir. All recovered, but all developed transaminase elevations (61) . A 

These supportive in vitro data have spurred use of both chloroquine and hydroxychloroquine offlabel and in multiple randomized trials. Until late March 2020, supportive human data were limited to announcement of "more than 100 patients [demonstrating] that chloroquine phosphate is superior to the control treatment in inhibiting the exacerbation of pneumonia, improving lung imaging findings, promoting a virus-negative conversion, and shortening the disease course," from Chinese health authorities with no presentation of primary data (71) . Since, limited primary data from small randomized controlled trials and observational studies have become available with conflicting results (72) (73) (74) (75) (76) (77) . A randomized trial was performed at Wuhan University and included 62 adults with mild illness (defined as no supplemental oxygen requirement but radiographic evidence of pneumonia on computed tomography scan). Thirty-one were randomized to hydroxychloroquine 400 mg daily for five days plus standard care, and the other 31 patients received standard care only.

"Standard care" in this study was broadly defined as use of antiviral agents, antibacterial agents, and A c c e p t e d M a n u s c r i p t 26 immunoglobulin, with or without steroids. The primary endpoints were measured five days after randomization. Time to clinical improvement was shorter in the hydroxychloroquine-treated patients compared with the control group (fever, 2.2 days versus 3.2 days; cough, 2.0 days vs 3.1 days; and radiographic improvement, 81% versus 55%) (72) . This study has not yet undergone peer review at the time of writing of this guidance. A second randomized trial enrolled 150 patients from 16 Chinese hospitals and compared clinical and virologic outcomes between those treated with hydroxychloroquine 1200 mg daily for three days, followed by 800 mg daily for 2 or 3 weeks-a higher dose and substantially longer duration than those used in other studies-as compared to standard care. Randomization was stratified based on illness severity, and mild, moderate, and severe cases were included. The primary outcome was virologic clearance by PCR from respiratory secretions at day 28, with key secondary outcomes including fever resolution (<36.6C), attainment of normal oxygen saturation, and resolution of respiratory symptoms. There was no difference in virologic clearance by PCR at 28 days (85% versus 81%) or time to virologic clearance between the two groups (median of 8 versus 7 days). Further, while the authors report improved clinical outcomes, this difference seems only qualitatively apparent during the second week of therapy and on a post-hoc analysis limited to 28 patients not treated with other antivirals (73) . This study also has not undergone peer review. Finally, a smaller randomized trial compared 15 patients who were treated with chloroquine to 15 treated with standard therapy. While no difference was detected in virologic clearance seven days after randomization (87% versus 93%), it is difficult to view this as a "negative" trial, given the high cure rate in the control group (74) . The authors also presented a subgroup analysis comparing six patients who received both hydroxychloroquine and azithromycin to 14 patients receiving hydroxychloroquine alone. Six of six patients (100%) treated with combination therapy were PCR negative on day 6, as compared to eight of 14 (57%) in the hydroxychloroquine monotherapy group. However, the azithromycin-treated patients had significantly higher viral cycle thresholds at baseline, suggesting that they had a lower baseline viral load and were more likely to experience viral clearance, independent of azithromycin use (76) . While this manuscript was published in a peer-reviewed journal, individuals and professional societies have raised concerns about the authors' conclusions (78) .

A c c e p t e d M a n u s c r i p t 28 A larger case series was published by the same group, which reported clinical and virologic outcomes for 80 patients with mild to moderate disease treated with the same combination of hydroxychloroquine and azithromycin. While 83% of patients in the study tested negative for SARS-CoV-2 by PCR by day 7, it is difficult to draw any conclusions related to efficacy given that there was no control group and individual-level cycle thresholds were not reported (77) . Another group of investigators performed a similar study evaluating virologic clearance at day 7 in 11 hospitalized adults (10 of whom required supplemental oxygen) treated with hydroxychloroquine and azithromycin. In contrast to the findings of Gautret et al., 80% of survivors were persistently positive for SARS-CoV-2 after six days of therapy. While a small, uncontrolled study, these data raise the possibility that the rapid virologic clearance observed in the Gautret et al. study could perhaps have been driven by the relatively mild illness severity, and perhaps correspondingly high baseline viral cycle thresholds, of included patients (79) . Finally, emerging data demonstrate that QTc prolongation >40 ms occurs in up to 30% of patients receiving the combination of hydroxychloroquine and azithromycin, with 11% developing QTc prolongation >500 ms (63) . Further highlighting safety concerns, an RCT comparing safety of high-dose chloroquine (600 mg twice daily for 10 days) versus low-dose chloroquine (450 mg twice daily on day 1, followed by 450 mg daily for a total of 5 days) in combination with azithromycin demonstrated more frequent QTc prolongation >500 ms (19%) and higher mortality in the high-dose arm, leading to termination of that treatment arm (64) . Of note, patients randomized to the high-dose treatment arm more often had underlying cardiovascular disease.

There are 15 US-based trials evaluating hydroxychloroquine, including seven evaluating the effect of pre-or post-exposure prophylaxis in various populations (NCT04308668, NCT04333732, NCT04328467, NCT04328961, NCT04335084, NCT04318444, NCT04333225) and seven evaluating A c c e p t e d M a n u s c r i p t 29 efficacy for treatment (three of which include azithromycin) (NCT04329832, NCT04334382, NCT04335552, NCT04334967, NCT04334512, NCT04333654, NCT04332991). One trial (NCT04335552) includes adolescents >12 years of age.

Guidance statement: The panel suggests a hydroxychloroquine dosing regimen that includes a loading dose on day 1 and a total duration of no more than five days.

Rationale: We suggest one of two dosing regimens ( Table 4) , both of which incorporate a loading dose and no more than five days of therapy. This suggestion is based on the pharmacokinetic (PK) characteristics of hydroxychloroquine. The first is the dosing and duration used for acute uncomplicated malaria, with the option of extending to a total of five days. This three-day regimen has the advantage of substantial clinical experience and a track record of safety, which should be prioritized when administering therapy with unknown efficacy but significant potential for toxicity.

The second is the dosing and duration proposed by Yao et al. based on physiologically based pharmacokinetics (PBPK) modeling (67) . The divided daily doses offer the additional advantage of perhaps minimizing gastrointestinal side effects.

There is a lack of data to support a specific dosing regimen or duration of therapy for treatment of SARS-CoV-2. Relevant PK properties of the drug to consider when making dosing and duration determinations include a large volume of distribution and a long terminal half-life of up to 40 days (80) . As a result, it takes several weeks to achieve steady-state with once-daily dosing. Administering A c c e p t e d M a n u s c r i p t 30 a loading dose, or higher dosages on day 1, may therefore be beneficial to more rapidly achieve peak plasma concentrations, especially when treating an acute infection like SARS-CoV-2. Yao and colleagues performed simulations based on PBPK modeling using human population PK and rat lung drug penetration data. All simulated hydroxychloroquine dosing regimens tested achieved high trough lung:EC 50 ratios. The authors concluded that a dose of 400 mg twice daily on day 1, followed by a maintenance dose of 200 mg given twice daily for four days, would be ideal for adult patients to balance efficacy, safety, and compliance (67) . Pediatric simulations were not reported.

Dosing currently approved for treatment of acute malaria has the advantage of decades of clinical experience and safety. Additionally, based on Monte Carlo simulations, the acute malaria dosing regimen is more likely to achieve rapid peak plasma concentrations, which may be beneficial when treating an acute infection such as COVID-19 (81) .

Optimal treatment duration is similarly uncertain, with five days being most commonly used in published reports, but anywhere from 3-14 days reported (51, 71, (82) (83) (84) (85) . Given the very long halflife of the drug, short courses of 3-5 days are likely to be of sufficient duration to treat an acute viral infection. Underscoring the importance of short durations of therapy, hydroxychloroquine has been associated with dose-dependent toxicities, including life-threatening cardiac arrhythmias, hemolysis, and retinopathy, though both hemolysis and retinopathy are extraordinarily rare with short durations of therapy (86, 87) . Rationale: Available data from small studies suggest the risk of hemolysis is low among patients with G6PD deficiencies who receive hydroxychloroquine (88, 89) . G6PD screening is not performed routinely for patients receiving hydroxychloroquine for FDA-approved indications (e.g., malaria, rheumatologic conditions) (90, 91) . If providers elect to screen for G6PD deficiency, initiation of therapy should not be delayed while awaiting this result. Patients with G6PD deficiencies should be monitored for hemolysis during hydroxychloroquine therapy. A c c e p t e d M a n u s c r i p t 32 Some panelists raised concerns that patients in this trial were severely ill and treated late in their disease course, suggesting that these findings were not generalizable to children with less severe disease, such that lopinavir-ritonavir may be an option for children unable to receive remdesivir or hydroxychloroquine. Others believed that that these data, coupled with the questionable efficacy in vitro and in animal studies, were sufficient to exclude a significant possibility of benefit in pediatric populations, such that lopinavir-ritonavir should not be considered an option in any scenario. A further consideration raised by the panelists was the harms resulting from exacerbating drug shortages for children with HIV, a pediatric infection for which lopinavir-ritonavir has demonstrated efficacy. Use of lopinavir-ritonavir with ribavirin raised concerns due to the risk of ribavirin toxicity and lack of clear efficacy data for this agent, and this combination is not recommended by the panel.

Lopinavir-ritonavir is a protease inhibitor FDA approved for treatment of pediatric HIV. The ritonavir component inhibits the CYP3A metabolism of lopinavir, increasing plasma levels of lopinavir. It is a preferred therapy for children 2 weeks to 3 years of age who require antiretroviral therapy and an alternative therapy for children >3 years of age (93, 94) . Lopinavir-ritonavir is generally welltolerated, with the most common adverse drug reactions (ADRs) being dysgeusia (i.e., a distorted sense of taste), nausea, vomiting, and diarrhea, with serious ADRs (hepatotoxicity, QTc prolongation, and AV block) rarely reported (95) (96) (97) (98) . Its hypothesized mechanism of action for SARS-CoV-2 is inhibition of the viral proteinases papain-like proteinase and 3C-like proteinase, which are key enzymes in coronavirus polyprotein processing. In a mouse model of MERS-CoV, lopinavir-ritonavir combined with IFN-β administered one day prior to infection slightly reduced viral titers but did not impact lung function or weight loss. Lopinavirritonavir and IFN-β given one day after infection improved pulmonary function but failed to reduce viral replication, lung hemorrhaging, or viral titers (56) . In a non-human primate model of MERS-CoV, animals treated with lopinavir-ritonavir were compared to untreated animals, animals treated with mycophenolate mofetil (MMF), and animals treated with IFN-β1b. The lopinavir-ritonavir-treated animals had better clinical scores, less weight reduction, and less pulmonary infiltrate than untreated animals and animals treated with MMF. Furthermore, necropsied lung and extrapulmonary tissues from the treated group had lower mean viral loads than those of animals in the comparator groups (108) .

A c c e p t e d M a n u s c r i p t 34

A matched cohort study including 75 patients with SARS-CoV-1 compared mortality and rates of intubation between patients treated with lopinavir-ritonavir initially (N=44), patients treated with lopinavir-ritonavir as rescue therapy (after worsening oxygen saturation, dyspnea, radiographic findings, and after failure of pulse steroids) (N=31), and historical controls receiving standard therapy (including ribavirin and steroids). Matching criteria included age strata, sex, presence of comorbid medical conditions, lactate dehydrogenase (LDH), and for the group who received lopinavir-ritonavir as a rescue therapy, use of steroids. Lopinavir-ritonavir as an initial treatment (in combination with ribavirin, as part of standard therapy) was associated with reduced mortality (2.3% vs 15.6%) and mechanical ventilation (0% vs 11%) compared with the standardized rates in the matched cohort. The mortality, oxygen desaturation, and intubation rates of the subgroup of patients who received lopinavir-ritonavir as rescue therapy were not different from those in the matched cohort receiving standard therapy (109) .

A second observational study in SARS-CoV-1 compared 41 patients treated with lopinavir-ritonavir for 10-14 days, ribavirin, and steroids to 111 historical control patients treated with ribavirin and steroids only. The treatment group was further divided into those treated with lopinavir-ritonavir as initial therapy (before needing pulse steroids, which were given for worsening respiratory symptoms in both groups) (N=12) and as "rescue" therapy (after pulse steroids) (N=29). The rate of ARDS or death at 21 days was significantly lower in the lopinavir-ritonavir treatment group (1/41, 2.4%) than historical controls (32/111, 28.8%). In addition, the lopinavir-ritonavir group had a progressive decrease in viral load, an early rise in lymphocyte count, a reduction in the cumulative dose of pulsed methylprednisolone, and fewer episodes of nosocomial infections. Of note, gastrointestinal ADRs occurred in 11 (26%) patients, including one patient who had to stop therapy due to elevated alanine aminotransferase levels. Hemoglobin reductions >2 g/dl occurred in 70%, potentially due to A c c e p t e d M a n u s c r i p t 35 concomitant ribavirin. Like the prior study, the pre/post design introduces the opportunity for confounding due to improvement in recognition and management of SARS-CoV-1 patients later in the epidemic. Further, the small number of exposed patients limited the ability to adjust for many confounders, aside from admission LDH (105) .

The highest quality human study in SARS-CoV-2 is a randomized controlled trial conducted in There was no difference in time to clinical improvement in the intention-to-treat population (16 days versus 16 days). No difference in the primary outcome was identified when the group was stratified into those treated within 12 days of illness onset and those treated beyond 12 days, with 13 days being the median duration of symptoms prior to randomization. There was no difference in 28-day mortality (19.2% versus 25%; difference, 5.8%; 95% CI, -17.3 to 5.7) or virologic outcome between the two groups, but the lopinavir-ritonavir-treated patients had a shorter ICU length of stay (six days versus 11 days) (92) . Concerns about the generalizability of these findings include: 1) lopinavirritonavir was started late in the disease course (median of 13 days after symptom onset), while animal and human data from other coronaviruses suggested that early antiviral initiation is important; 2) higher baseline viral loads in the treatment arm, though there was no difference in the change from baseline across the two arms; and 3) a high mortality rate in this cohort, perhaps limiting ability to extrapolate these data to other, less sick patients.

A c c e p t e d M a n u s c r i p t 36 There are additionally several published case reports and case series describing patients treated with lopinavir-ritonavir, including a series of 36 children in which 14 were treated with lopinavir-ritonavir.

All patients recovered, and no comparisons were made between treated and untreated patients (110) . Several additional adult case series report favorable clinical outcomes among lopinavirritonavir-treated patients, but illness severity, concomitant therapies, and the lack of comparator groups preclude any statement of efficacy (111) (112) (113) . Notably, in the largest series, only one of six patients treated with lopinavir-ritonavir was able to complete therapy due to gastrointestinal adverse events (111) .

As of April 14, 2020, there are no US-based clinical trials registered on clinicaltrials.gov evaluating lopinavir-ritonavir for the treatment of COVID-19, though there are multiple ongoing and planned trials in other countries.

Published data from large epidemiologic studies suggest that the overwhelming majority of children with COVID-19 experience a relatively mild and self-limited illness, with rare reports of critical illness and (thus far) near non-existent mortality. As of April 14, 2020, there are no antiviral therapies with proven efficacy for COVID-19. Absent an opportunity to participate in a clinical trial, use of investigational agents for treatment of COVID-19 through Single Patient Expanded Access requests or off-label use of medications currently approved by the FDA for other indications is possible, but such use appears to be unnecessary in most cases. Pediatricians and pediatric ID providers should therefore be guided by the principle of "first, do no harm" when considering antiviral therapy, reserving use for those children in whom the possibility for benefit outweighs risk of toxicity. Use of antivirals as part of randomized controlled trials to establish the efficacy and safety of these agents for treatment, prophylaxis, and as a strategy to reduce household transmission should be prioritized. M a n u s c r i p t 41

Coronavirus COVID-19 global cases by the Center for Systems Science and Engineering

Off-label use of medicines for COVID-19

Treating COVID-19-Off-label drug use, compassionate use, and randomized clinical trials during pandemics

COVID-19 infection in Iranian children: a case series of 9 patients

Detection of COVID-19 in children in early

Severe outcomes among patients with coronavirus disease 2019 (COVID-19) -United States

SHaring Antimicrobial Reports for Pediatric Stewardship (SHARPS): A quality improvement collaborative

Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19

Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults

Coronavirus infections in children including COVID-19: An overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children

The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) -China

MMWR Morb Mortal Wkly Rep

The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease

Coronavirus in the U.S.: Latest map and case count. The New York Times

Novel coronavirus infection in hospitalized infants under 1 year of age in China

Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding |

Coronavirus Disease 2019 (COVID-19) in Italy

A case series of children with 2019 novel coronavirus infection: Clinical and epidemiological features

Flash survey on SARS-CoV-2 infections in pediatric patients on anti-cancer treatment

Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China

Clinical characteristics of coronavirus disease 2019 in China

Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. The Lancet

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures

Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis

The burden of influenza hospitalizations in infants from

Influenza in children with special risk medical conditions: A systematic review and meta-analysis

Parainfluenza virus type 4: case report and review of the literature

The burden of respiratory syncytial virus infection in young children

Rates of hospitalization for respiratory syncytial virus infection among children in medicaid

Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of admission and management variation in patients hospitalized with respiratory syncytial viral lower respiratory tract infection

Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children

The differential clinical impact of human coronavirus species in children with cystic fibrosis

Obesity and COVID-19 severity in a designated hospital in Shenzhen

Social Science Research Network

COVID-19 in a long-term care facility -King County

Clinical findings of patients with coronavirus disease

Social Science Research Network

Sleep-disordered breathing in overweight and obese children and adolescents: prevalence, characteristics and the role of fat distribution

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

Reninangiotensin-aldosterone system inhibitors in patients with COVID-19

A randomized, controlled trial of ebola virus disease therapeutics

Ad-hoc Expert Consultation on clinical trials for Ebola Therapeutics

Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics

Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. Subbarao K, editor. mBio

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus

Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection

Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine c-nucleoside (gs-5734) for the treatment of Ebola and emerging viruses

First case of 2019 novel coronavirus in the United States

First 12 patients with coronavirus disease 2019 (COVID-19) in the United States

Compassionate use of remdesivir for patients with severe COVID-19

The QT interval in patients with SARS-CoV-2 infection treated with hydroxychloroquine/azithromycin. medRxiv

Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study). medRxiv

Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study. medRxiv

Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases

In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

Evaluation of immunomodulators, interferons and known in vitro SARS-CoV inhibitors for inhibition of SARS-CoVreplication in BALB/c mice

Paradoxical effect of chloroquine treatment in enhancing chikungunya virus infection. Viruses

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv

Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. medRxiv

A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)

No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial. medRxiv

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study

Statement on IJAA paper | International Society of Antimicrobial Chemotherapy

No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Médecine Mal Infect

Bioavailability of hydroxychloroquine tablets in healthy volunteers

Rational dosing of HCQ for COVID-19_pre-print

Diagnosis and treatment protocol for novel coronavirus pneumonia

A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19

Italian Society of Infectious Diseases and Tropical Diseases COVID-19 Guideline

Multicenter Collaboration Group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia

Zhonghua Jie He He Hu Xi Za Zhi Zhonghua Jiehe He Huxi Zazhi Chin J Tuberc Respir Dis

Recommendations on screening for chloroquine and hydroxychloroquine retinopathy -2016

Examination of hydroxychloroquine use and hemolytic anemia in G6PDH-deficient patients

Updated recommendations on the use of hydroxychloroquine in dermatologic practice

Guidelines for the treatment of malaria

American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol Hoboken NJ

A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19

Regimens Recommended for Initial Therapy of Antiretroviral-Naive Children What to Start Pediatric ARV

Lopinavir/Ritonavir Protease Inhibitors (PIs) Pediatric ARV

Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children

Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children

Pediatric Postmarketing Pharmacovigilance Review: Kaletra

Lopinavir plasma concentrations and virological outcome with lopinavir-ritonavir monotherapy in HIV-1-infected patients

Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro

Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East Respiratory Syndrome coronavirus replication in cell culture

Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS-CoV 3CL(pro) inhibitors

Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs

In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings

HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus

Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus

Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset

Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study

Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study

Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore

Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment

Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: The application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR

The authors thank the SHaring Antimicrobial Reports for Pediatric Stewardship (SHARPS)Collaborative for facilitating this work. We are especially grateful to Cindy Terrill and Mirela Grabic for their invaluable logistical support.The authors have no associations that might pose a conflict of interest.

A c c e p t e d M a n u s c r i p t 38 A c c e p t e d M a n u s c r i p t 42 A c c e p t e d M a n u s c r i p t 43 A c c e p t e d M a n u s c r i p t 44 A c c e p t e d M a n u s c r i p t 45 A c c e p t e d M a n u s c r i p t 46 A c c e p t e d M a n u s c r i p t 47 

There is insufficient evidence to suggest that young age alone is a risk factor for severe COVID-19.

There is insufficient evidence to establish that severely immunocompromised children are at higher risk for severe COVID-19. Based on adult studies of COVID-19 and extrapolation from other viral infections, children with severe immunocompromise may be more likely to experience severe illness or prolonged viral shedding from COVID-19.

There is insufficient evidence demonstrating that mildly or moderately immunocompromised children are at higher risk for severe COVID-19.

There is insufficient evidence demonstrating that children with underlying cardiac disease are at higher risk for severe COVID-19.Based on adult studies of COVID-19 and extrapolation from other viral infections, children with significant underlying cardiac disease may be more likely to experience severe illness.

There is insufficient evidence that children with underlying pulmonary disease are at higher risk for severe COVID-19. Based on adult studies of COVID-19 and extrapolation from other viral infections, children with significant underlying pulmonary disease may be more likely to experience severe illness.

There is insufficient evidence that either overweight or obesity alone is a risk factor for severe COVID-19 in the pediatric population. Additional considerations include the presence of comorbidities, including diabetes; hypertension; cardiovascular, pulmonary, renal, or liver disease; and cancer.

There is insufficient evidence to suggest that either type 1 or type 2 diabetes alone is a risk factor for severe COVID-19 in the pediatric population. Additional considerations include the degree of glycemic control and presence of associated comorbidities (e.g., cardiovascular or renal disease, or transplantation).A c c e p t e d M a n u s c r i p t 49 

 Alemtuzumab (<6 months)  ATG (<3 months)  Co-stimulation inhibitors (e.g., belatacept, abatacept) for maintenance immunosuppression  High-dose corticosteroids (e.g., ≥2mg/kg/day prednisone-equivalent for >2 weeks)  Expected profound T-cell dysfunction or ALC <100/mm 3 A c c e p t e d M a n u s c r i p t 50 Severe underlying pulmonary disease  Listed for lung transplant  Oxygen on non-invasive ventilation while awake or asleep for lung disease, heart disease, or pulmonary hypertension  Severe chronic respiratory disease (including cystic fibrosis, bronchopulmonary dysplasia, interstitial or diffuse lung disease, bronchiectasis, scoliosis, congenital diaphragmatic hernia, pulmonary hypoplasia) with >3 hospitalizations in the last 12 months  Severe neuromuscular disease resulting in impaired airway clearance/cough (for example, SMA, Duchenne's and other muscular dystrophies)  Severe persistent asthma Recommend against combination therapy with ribavirin.